Aegis AcuRiseID™ was designed to help clinicians identify and overcome adherence barriers in the treatment of mental illness.
Adherence monitoring is available for many medications utilized in the treatment of behavioral health conditions so that clinicians can customize their testing order to the medications and substances most appropriate. Monitoring can be expanded or reduced according to the individual’s risk of adverse outcomes or substance misuse.
Contact us for more information on our complete flexible test menu.
Individuals who are prescribed self-administered medications only take about 50% of their doses.11. Nieuwlaat et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2014. Issue 11. Art. No.: CD000011. doi: 10.1002/14651858.CD000011.pub4.).
Across the U.S. economy, mental illness causes $193.2 billion in lost earnings each year.22. Mental Health By the Numbers. National Alliance on Mental Illness. Updated June 2022. Accessed March 13, 2023. https://www.nami.org/mhstats
1 in 15 (17 million) U.S. adults experienced a co-occurring substance use disorder and mental illness.11. Nieuwlaat et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2014. Issue 11. Art. No.: CD000011. doi: 10.1002/14651858.CD000011.pub4.).
Dr. Jane Weinberg, Psychiatrist
Nashville, TN
Patients may attempt to submit synthetic urine in place of their own urine, which makes it impossible to assess adherence with prescribed therapy. BioDetect testing confirms whether the sample is consistent with human urine. (Included on every urine sample.)
PainComp results along with InterACT Rx testing can objectively detect causes of drug-drug interactions and help you avoid harmful adverse drug events (ADEs) in your patients.
Patients may seek additional therapy for pain or anxiety or may look for recreational use of substances they believe cannot be detected by traditional toxicology testing. Aegis’s Novel Psychoactive Substance testing can reveal the use of many designer drugs, some of which may even be unknown to the patient.
Depending on the type of care provided at a given practice site, additional clinical blood testing services can help with continuity of care. Contact your local Aegis representative to find out if these services are a good fit for your practice.
Patients may attempt to submit synthetic urine in place of their own urine, which makes it impossible to assess adherence with prescribed therapy. BioDetect testing confirms whether the sample is consistent with human urine. (Included on every urine sample.)
PainComp results along with InterACT Rx testing can objectively detect causes of drug-drug interactions and help you avoid harmful adverse drug events (ADEs) in your patients.
Patients may seek additional therapy for pain or anxiety or may look for recreational use of substances they believe cannot be detected by traditional toxicology testing. Aegis’s Novel Psychoactive Substance testing can reveal the use of many designer drugs, some of which may even be unknown to the patient.
Depending on the type of care provided at a given practice site, additional clinical blood testing services can help with continuity of care. Contact your local Aegis representative to find out if these services are a good fit for your practice.